<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01660022</url>
  </required_header>
  <id_info>
    <org_study_id>MMV_OZ439_12_002</org_study_id>
    <nct_id>NCT01660022</nct_id>
  </id_info>
  <brief_title>Safety Tolerability &amp; Pharmacokinetics of Co-administered Single Doses of OZ439 &amp; Piperaquine to Healthy Subjects</brief_title>
  <official_title>A Phase I Study to Investigate the Safety, Tolerability &amp; Pharmacokinetics of Co-administered Single Doses of OZ439 and Piperaquine to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cross Research S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I Study to investigate the safety, tolerability &amp; pharmacokinetics of co-administered
      single doses of OZ439 and Piperaquine to healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Placebo-controlled, double-blind, five-cohort, 2-period (per cohort) dose-escalation study.

      For each subject, the study included a screening evaluation (within 21 days of the 1st dose),
      dosing on 2 separate occasions (Period 1 and Period 2) and a follow-up visit (6 weeks
      following the final dose).

      Within each cohort, subjects were randomised into two sequences to receive OZ439 in Period 1
      and OZ439 plus piperaquine in Period 2 (sequence 1, 8 subjects) or OZ439-matching placebo in
      Period 1 and OZ439/piperaquine matching placebos in Period 2 (sequence 2, 4 subjects).

      Safety and tolerability were evaluated: Physical examination, ECG assessments including a
      full baseline matched profile of ECG tracings, vital signs, laboratory evaluations, in
      particular liver function tests and adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OZ439 Cmax</measure>
    <time_frame>Up to 168 hours post-dose</time_frame>
    <description>OZ439 Maximum concentration level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Piperaquine Cmax</measure>
    <time_frame>Up to 1008 hours post-dose (Day 43)</time_frame>
    <description>Piperaquine Maximum concentration level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OZ439 AUC(0-168)</measure>
    <time_frame>Up to 168 hours post-dose</time_frame>
    <description>Area under the plasma concentration versus time curve to 168 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OZ439 t1/2</measure>
    <time_frame>Up to 168 hours post-dose</time_frame>
    <description>OZ439 Elimination half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Piperaquine AUC(0-168)</measure>
    <time_frame>Up to 1008 hours post-dose (Day 43)</time_frame>
    <description>Piperaquine area under the plasma concentration versus time curve to 168 hours post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Piperaquine t1/2</measure>
    <time_frame>Up to 1008 hours post-dose (Day 43)</time_frame>
    <description>Piperaquine Elimination half-life (t1/2).</description>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>OZ439 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg OZ439 single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OZ439 100 mg + PQP 160mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg OZ439 single oral dose + 160mg Piperaquine single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OZ439 100 mg + PQP 480mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg OZ439 single oral dose + 480mg Piperaquine single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OZ439 100 mg + PQP 1440mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100mg OZ439 single oral dose + 1440mg Piperaquine single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OZ439 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg OZ439 single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OZ439 300 mg + PQP 1440mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg OZ439 single oral dose + 1440mg Piperaquine single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OZ439 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800mg OZ439 single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OZ439 800 mg + PQP 1440mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800mg OZ439 single oral dose + 1440mg Piperaquine single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100mg OZ439 single oral dose</intervention_name>
    <description>100mg OZ439 oral suspension single dose</description>
    <arm_group_label>OZ439 100mg</arm_group_label>
    <arm_group_label>OZ439 100 mg + PQP 160mg</arm_group_label>
    <arm_group_label>OZ439 100 mg + PQP 480mg</arm_group_label>
    <arm_group_label>OZ439 100 mg + PQP 1440mg</arm_group_label>
    <other_name>OZ439</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>300 mg OZ439 single oral dose</intervention_name>
    <description>300mg OZ439 oral suspension single dose</description>
    <arm_group_label>OZ439 300mg</arm_group_label>
    <arm_group_label>OZ439 300 mg + PQP 1440mg</arm_group_label>
    <other_name>OZ439</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>160mg Piperaquine single oral dose</intervention_name>
    <description>160 mg Piperaquine tablet</description>
    <arm_group_label>OZ439 100 mg + PQP 160mg</arm_group_label>
    <other_name>Piperaquine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>480mg Piperaquine single oral dose</intervention_name>
    <description>480 mg Piperaquine tablet</description>
    <arm_group_label>OZ439 100 mg + PQP 480mg</arm_group_label>
    <other_name>Piperaquine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1440mg Piperaquine single oral dose</intervention_name>
    <description>1440 mg Piperaquine tablet</description>
    <arm_group_label>OZ439 100 mg + PQP 1440mg</arm_group_label>
    <arm_group_label>OZ439 300 mg + PQP 1440mg</arm_group_label>
    <arm_group_label>OZ439 800 mg + PQP 1440mg</arm_group_label>
    <other_name>Piperaquine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>800 mg OZ439 single oral dose</intervention_name>
    <description>800mg OZ439 oral suspension single dose</description>
    <arm_group_label>OZ439 800mg</arm_group_label>
    <arm_group_label>OZ439 800 mg + PQP 1440mg</arm_group_label>
    <other_name>OZ439</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males &amp; females, 18-55 years old

          -  BMI 18 to 30kg/m2; total body weight &gt;50kg

          -  Healthy, determined by pre-study medical history, physical examination vital signs, 12
             Lead ECG

          -  Females of non-childbearing potential.

          -  Males must agree to use a double barrier method of contraception

          -  Lab tests at screening within the reference ranges

        Exclusion Criteria:

          -  Any condition that could affect drug absorption, e.g. gastrectomy, diarrhea

          -  Clinically relevant abnormalities in ECG

          -  Family history of sudden death or of congenital prolongation of QTc interval - History
             of symptomatic cardiac arrhythmias or with clinically relevant bradycardia

          -  Electrolyte disturbances

          -  History of drug or alcohol abuse, tobacco users

          -  Participation in evaluation of any drug for 3 months before the study

          -  Administration of ANY systemic medication/herbal product within 14 days of first dose
             of study drug.

          -  unaccustomed strenuous exercise within 7 days of any study visit

          -  Alcohol consumption within 24 hours of any study visit

          -  Consumption of any fruit juice or food containing grapefruit within 7 days

          -  Positive test for HIV-1, HBsAg or HCV

          -  Positive urine drug screen at Screening or admission

          -  Severe allergies/multiple drug allergies

          -  Volunteers who have donated blood or experienced significant blood loss within 90 days
             of screening

          -  Hemoglobin below lower limit of the reference range

          -  Clinically relevant abnormal lab values indicative of physical illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milko M Radicioni, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cross Research S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cross Research S.A.</name>
      <address>
        <city>Mendrisio</city>
        <zip>CH 6850</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2012</study_first_submitted>
  <study_first_submitted_qc>August 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2012</study_first_posted>
  <results_first_submitted>December 15, 2014</results_first_submitted>
  <results_first_submitted_qc>January 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 21, 2015</results_first_posted>
  <last_update_submitted>January 7, 2015</last_update_submitted>
  <last_update_submitted_qc>January 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Piperaquine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Date of first enrolment: 11SEP2012 Date last volunteer completed: 07MAY2013 Phase 1 Clinical Research Unit</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>Sequence 1: OZ439 100mg Sequence 2: OZ439 100mg / PQP 160mg</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>Sequence 1: OZ439 100mg Sequence 2: OZ439 100mg+PQP 480mg</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3</title>
          <description>Sequence 1: OZ439 100mg Sequence 2: OZ439 100mg+PQP 1440mg</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4</title>
          <description>Sequence 1: OZ439 300mg Sequence 2: OZ439 300mg+PQP 1440mg</description>
        </group>
        <group group_id="P5">
          <title>Cohort 5</title>
          <description>Sequence 1: OZ439 800mg Sequence 2: OZ439 800mg+PQP 1440mg</description>
        </group>
        <group group_id="P6">
          <title>Placebo</title>
          <description>Cohorts 1, 2, 3, 4 and 5</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Sequence (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Sequence (42 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>Sequence 1: OZ439 100mg Sequence 2: OZ439 100 mg / PQP 160 mg</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2</title>
          <description>Sequence 1: OZ439 100mg Sequence 2: OZ439 100 mg / PQP 480 mg</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3</title>
          <description>Sequence 1: OZ439 100mg Sequence 2: OZ439 100 mg / PQP 1440 mg</description>
        </group>
        <group group_id="B4">
          <title>Cohort 4</title>
          <description>Sequence 1: OZ439 300mg Sequence 2: OZ439 300 mg / PQP 1440 mg</description>
        </group>
        <group group_id="B5">
          <title>Cohort 5</title>
          <description>Sequence 1: OZ439 800mg Sequence 2: OZ439 800 mg / PQP 1440 mg</description>
        </group>
        <group group_id="B6">
          <title>Placebo</title>
          <description>Cohorts 1, 2, 3, 4 and 5</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="20"/>
            <count group_id="B7" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.0" spread="9.4"/>
                    <measurement group_id="B2" value="41.7" spread="7.1"/>
                    <measurement group_id="B3" value="35.4" spread="10"/>
                    <measurement group_id="B4" value="32.1" spread="8.4"/>
                    <measurement group_id="B5" value="35.7" spread="11.7"/>
                    <measurement group_id="B6" value="37.3" spread="10.3"/>
                    <measurement group_id="B7" value="36.43" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>OZ439 Cmax</title>
        <description>OZ439 Maximum concentration level</description>
        <time_frame>Up to 168 hours post-dose</time_frame>
        <population>All randomised subjects who fulfilled the study protocol requirements in terms of study drug intake and PK samplings, with no major deviations that could affect the PK results.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - OZ439 100mg</title>
            <description>Cohort 1 - Sequence 1 OZ439 100mg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - OZ439 100mg / PQP 160mg</title>
            <description>Cohort 1 - Sequence 2 OZ439 100mg / PQP 160mg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 - OZ439 100mg</title>
            <description>Cohort 2 - Sequence 1 OZ439 100mg</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 - OZ439 100mg / PQP 480mg</title>
            <description>Cohort 2 - Sequence 2 OZ439 100mg / PQP 480mg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 - OZ439 100mg</title>
            <description>Cohort 3 - Sequence 1 OZ439 100mg</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 - OZ439 100mg / PQP 1440mg</title>
            <description>Cohort 3 - Sequence 2 OZ439 100mg / PQP 1440mg</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 - OZ439 300mg</title>
            <description>Cohort 4 - Sequence 1 OZ439 300mg</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 - OZ439 300mg / PQP 1440mg</title>
            <description>Cohort 4 - Sequence 2 OZ439 300mg / PQP 1440mg</description>
          </group>
          <group group_id="O9">
            <title>Cohort 5 - OZ439 800mg</title>
            <description>Cohort 5 - Sequence 1 OZ439 800mg</description>
          </group>
          <group group_id="O10">
            <title>Cohort 5 - OZ439 800mg / PQP 1440mg</title>
            <description>Cohort 5 - Sequence 2 OZ439 800mg / PQP 1440mg</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 Cmax</title>
          <description>OZ439 Maximum concentration level</description>
          <population>All randomised subjects who fulfilled the study protocol requirements in terms of study drug intake and PK samplings, with no major deviations that could affect the PK results.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142" spread="39.2"/>
                    <measurement group_id="O2" value="139" spread="33.1"/>
                    <measurement group_id="O3" value="146" spread="43.2"/>
                    <measurement group_id="O4" value="198" spread="47.4"/>
                    <measurement group_id="O5" value="127" spread="22.9"/>
                    <measurement group_id="O6" value="199" spread="26.8"/>
                    <measurement group_id="O7" value="590" spread="31.5"/>
                    <measurement group_id="O8" value="778" spread="31.5"/>
                    <measurement group_id="O9" value="1500" spread="42.2"/>
                    <measurement group_id="O10" value="1650" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Piperaquine Cmax</title>
        <description>Piperaquine Maximum concentration level</description>
        <time_frame>Up to 1008 hours post-dose (Day 43)</time_frame>
        <population>All randomised subjects who fulfilled the study protocol requirements in terms of study drug intake and PK samplings, with no major deviations that could affect the PK results.</population>
        <group_list>
          <group group_id="O1">
            <title>OZ439 100mg / PQP 160mg</title>
            <description>Cohort 1 - Sequence 2 OZ439 100mg / PQP 160mg</description>
          </group>
          <group group_id="O2">
            <title>OZ439 100mg / PQP 480mg</title>
            <description>Cohort 2 - Sequence 2 OZ439 100mg / PQP 480mg</description>
          </group>
          <group group_id="O3">
            <title>OZ439 100mg / PQP 1440mg</title>
            <description>Cohort 3 - Sequence 2 OZ439 100mg / PQP 1440mg</description>
          </group>
          <group group_id="O4">
            <title>OZ439 300mg / PQP 1440mg</title>
            <description>Cohort 4 - Sequence 2 OZ439 300mg / PQP 1440mg</description>
          </group>
          <group group_id="O5">
            <title>OZ439 800mg / PQP 1440mg</title>
            <description>Cohort 5 - Sequence 2 OZ439 800mg / PQP 1440mg</description>
          </group>
        </group_list>
        <measure>
          <title>Piperaquine Cmax</title>
          <description>Piperaquine Maximum concentration level</description>
          <population>All randomised subjects who fulfilled the study protocol requirements in terms of study drug intake and PK samplings, with no major deviations that could affect the PK results.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.59" spread="34.7"/>
                    <measurement group_id="O2" value="46.6" spread="44.3"/>
                    <measurement group_id="O3" value="393" spread="43.8"/>
                    <measurement group_id="O4" value="271" spread="30.9"/>
                    <measurement group_id="O5" value="356" spread="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OZ439 AUC(0-168)</title>
        <description>Area under the plasma concentration versus time curve to 168 hours post-dose.</description>
        <time_frame>Up to 168 hours post-dose</time_frame>
        <population>All randomised subjects who fulfilled the study protocol requirements in terms of study drug intake and PK samplings, with no major deviations that could affect the PK results.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - OZ439 100mg</title>
            <description>Cohort 1 - Sequence 1 OZ439 100mg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - OZ439 100mg / PQP 160mg</title>
            <description>Cohort 1 - Sequence 2 OZ439 100mg / PQP 160mg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 - OZ439 100mg</title>
            <description>Cohort 2 - Sequence 1 OZ439 100mg</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 - OZ439 100mg / PQP 480mg</title>
            <description>Cohort 2 - Sequence 2 OZ439 100mg / PQP 480mg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 - OZ439 100mg</title>
            <description>Cohort 3 - Sequence 1 OZ439 100mg</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 - OZ439 100mg / PQP 1440mg</title>
            <description>Cohort 3 - Sequence 2 OZ439 100mg / PQP 1440mg</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 - OZ439 300mg</title>
            <description>Cohort 4 - Sequence 1 OZ439 300mg</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 - OZ439 300mg / PQP 1440mg</title>
            <description>Cohort 4 - Sequence 2 OZ439 300mg / PQP 1440mg</description>
          </group>
          <group group_id="O9">
            <title>Cohort 5 - OZ439 800mg</title>
            <description>Cohort 5 - Sequence 1 OZ439 800mg</description>
          </group>
          <group group_id="O10">
            <title>Cohort 5 - OZ439 800mg / PQP 1440mg</title>
            <description>Cohort 5 - Sequence 2 OZ439 800mg / PQP 1440mg</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 AUC(0-168)</title>
          <description>Area under the plasma concentration versus time curve to 168 hours post-dose.</description>
          <population>All randomised subjects who fulfilled the study protocol requirements in terms of study drug intake and PK samplings, with no major deviations that could affect the PK results.</population>
          <units>ng.h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="862" spread="33.9"/>
                    <measurement group_id="O2" value="920" spread="26.6"/>
                    <measurement group_id="O3" value="1130" spread="41.7"/>
                    <measurement group_id="O4" value="1390" spread="47.0"/>
                    <measurement group_id="O5" value="909" spread="21.4"/>
                    <measurement group_id="O6" value="1520" spread="26.1"/>
                    <measurement group_id="O7" value="5740" spread="29.9"/>
                    <measurement group_id="O8" value="7410" spread="30.3"/>
                    <measurement group_id="O9" value="15300" spread="47.6"/>
                    <measurement group_id="O10" value="18600" spread="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OZ439 t1/2</title>
        <description>OZ439 Elimination half-life</description>
        <time_frame>Up to 168 hours post-dose</time_frame>
        <population>All randomised subjects who fulfilled the study protocol requirements in terms of study drug intake and PK samplings, with no major deviations that could affect the PK results.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - OZ439 100mg</title>
            <description>Cohort 1 - Sequence 1 OZ439 100mg</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - OZ439 100mg / PQP 160mg</title>
            <description>Cohort 1 - Sequence 2 OZ439 100mg / PQP 160mg</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 - OZ439 100mg</title>
            <description>Cohort 2 - Sequence 1 OZ439 100mg</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 - OZ439 100mg / PQP 480mg</title>
            <description>Cohort 2 - Sequence 2 OZ439 100mg / PQP 480mg</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3 - OZ439 100mg</title>
            <description>Cohort 3 - Sequence 1 OZ439 100mg</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3 - OZ439 100mg / PQP 1440mg</title>
            <description>Cohort 3 - Sequence 2 OZ439 100mg / PQP 1440mg</description>
          </group>
          <group group_id="O7">
            <title>Cohort 4 - OZ439 300mg</title>
            <description>Cohort 4 - Sequence 1 OZ439 300mg</description>
          </group>
          <group group_id="O8">
            <title>Cohort 4 - OZ439 300mg / PQP 1440mg</title>
            <description>Cohort 4 - Sequence 2 OZ439 300mg / PQP 1440mg</description>
          </group>
          <group group_id="O9">
            <title>Cohort 5 - OZ439 800mg</title>
            <description>Cohort 5 - Sequence 1 OZ439 800mg</description>
          </group>
          <group group_id="O10">
            <title>Cohort 5 - OZ439 800mg / PQP 1440mg</title>
            <description>Cohort 5 - Sequence 2 OZ439 800mg / PQP 1440mg</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 t1/2</title>
          <description>OZ439 Elimination half-life</description>
          <population>All randomised subjects who fulfilled the study protocol requirements in terms of study drug intake and PK samplings, with no major deviations that could affect the PK results.</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Insufficient data points for calculation</measurement>
                    <measurement group_id="O2" value="NA">Insufficient data points for calculation</measurement>
                    <measurement group_id="O3" value="NA">Insufficient data points for calculation</measurement>
                    <measurement group_id="O4" value="NA">Insufficient data points for calculation</measurement>
                    <measurement group_id="O5" value="NA">Insufficient data points for calculation</measurement>
                    <measurement group_id="O6" value="NA">Insufficient data points for calculation</measurement>
                    <measurement group_id="O7" value="90.6" spread="19.4"/>
                    <measurement group_id="O8" value="112" spread="45.2"/>
                    <measurement group_id="O9" value="65.4" spread="23.2"/>
                    <measurement group_id="O10" value="135" spread="53.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Piperaquine AUC(0-168)</title>
        <description>Piperaquine area under the plasma concentration versus time curve to 168 hours post-dose</description>
        <time_frame>Up to 1008 hours post-dose (Day 43)</time_frame>
        <population>All randomised subjects who fulfilled the study protocol requirements in terms of study drug intake and PK samplings, with no major deviations that could affect the PK results.</population>
        <group_list>
          <group group_id="O1">
            <title>OZ439 100mg / PQP 160mg</title>
            <description>Cohort 1 - Sequence 2 OZ439 100mg / PQP 160mg</description>
          </group>
          <group group_id="O2">
            <title>OZ439 100mg / PQP 480mg</title>
            <description>Cohort 2 - Sequence 2 OZ439 100mg / PQP 480mg</description>
          </group>
          <group group_id="O3">
            <title>OZ439 100mg / PQP 1440mg</title>
            <description>Cohort 3 - Sequence 2 OZ439 100mg / PQP 1440mg</description>
          </group>
          <group group_id="O4">
            <title>OZ439 300mg / PQP 1440mg</title>
            <description>Cohort 4 - Sequence 2 OZ439 300mg / PQP 1440mg</description>
          </group>
          <group group_id="O5">
            <title>OZ439 800mg / PQP 1440mg</title>
            <description>Cohort 5 - Sequence 2 OZ439 800mg / PQP 1440mg</description>
          </group>
        </group_list>
        <measure>
          <title>Piperaquine AUC(0-168)</title>
          <description>Piperaquine area under the plasma concentration versus time curve to 168 hours post-dose</description>
          <population>All randomised subjects who fulfilled the study protocol requirements in terms of study drug intake and PK samplings, with no major deviations that could affect the PK results.</population>
          <units>ng.h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1340">Not Calculated. Insufficient data points for calculation.</measurement>
                    <measurement group_id="O2" value="3420" spread="22.8"/>
                    <measurement group_id="O3" value="17500" spread="25.7"/>
                    <measurement group_id="O4" value="17200" spread="12.8"/>
                    <measurement group_id="O5" value="13200" spread="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Piperaquine t1/2</title>
        <description>Piperaquine Elimination half-life (t1/2).</description>
        <time_frame>Up to 1008 hours post-dose (Day 43)</time_frame>
        <population>All randomised subjects who fulfilled the study protocol requirements in terms of study drug intake and PK samplings, with no major deviations that could affect the PK results.</population>
        <group_list>
          <group group_id="O1">
            <title>OZ439 100mg / PQP 160mg</title>
            <description>Cohort 1 - Sequence 2 OZ439 100mg / PQP 160mg</description>
          </group>
          <group group_id="O2">
            <title>OZ439 100mg / PQP 480mg</title>
            <description>Cohort 2 - Sequence 2 OZ439 100mg / PQP 480mg</description>
          </group>
          <group group_id="O3">
            <title>OZ439 100mg / PQP 1440mg</title>
            <description>Cohort 3 - Sequence 2 OZ439 100mg / PQP 1440mg</description>
          </group>
          <group group_id="O4">
            <title>OZ439 300mg / PQP 1440mg</title>
            <description>Cohort 4 - Sequence 2 OZ439 300mg / PQP 1440mg</description>
          </group>
          <group group_id="O5">
            <title>OZ439 800mg / PQP 1440mg</title>
            <description>Cohort 5 - Sequence 2 OZ439 800mg / PQP 1440mg</description>
          </group>
        </group_list>
        <measure>
          <title>Piperaquine t1/2</title>
          <description>Piperaquine Elimination half-life (t1/2).</description>
          <population>All randomised subjects who fulfilled the study protocol requirements in terms of study drug intake and PK samplings, with no major deviations that could affect the PK results.</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294">Not Calculated. Insufficient data points for calculation.</measurement>
                    <measurement group_id="O2" value="283" spread="64.4"/>
                    <measurement group_id="O3" value="515" spread="36.3"/>
                    <measurement group_id="O4" value="632" spread="26.5"/>
                    <measurement group_id="O5" value="509" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From informed consent signature up to final study visit.</time_frame>
      <desc>Safety variables: treatment-emergent adverse events (TEAEs), ECG results, vital signs, laboratory evaluations, in particular liver function tests.</desc>
      <group_list>
        <group group_id="E1">
          <title>OZ439 100mg</title>
          <description>Cohorts 1, 2 and 3 OZ439 100mg</description>
        </group>
        <group group_id="E2">
          <title>OZ439 300mg</title>
          <description>Cohort 4 - Sequence 1 OZ439 300mg</description>
        </group>
        <group group_id="E3">
          <title>OZ439 800mg</title>
          <description>Cohort 5 - Sequence 1 OZ439 800mg</description>
        </group>
        <group group_id="E4">
          <title>OZ439 100mg / PQP 160mg</title>
          <description>Cohort 1 - Sequence 2 OZ439 100mg / PQP 160mg</description>
        </group>
        <group group_id="E5">
          <title>OZ439 100mg / PQP 480mg</title>
          <description>Cohort 2 - Sequence 2 OZ439 100mg / PQP 480mg</description>
        </group>
        <group group_id="E6">
          <title>OZ439 100mg / PQP 1440mg</title>
          <description>Cohort 3 - Sequence 2 OZ439 100mg / PQP 1440mg</description>
        </group>
        <group group_id="E7">
          <title>OZ439 300mg / PQP 1440mg</title>
          <description>Cohort 4 - Sequence 2 OZ439 300mg / PQP 1440mg</description>
        </group>
        <group group_id="E8">
          <title>OZ439 800mg / PQP 1440mg</title>
          <description>Cohort 5 - Sequence 2 OZ439 800mg / PQP 1440mg</description>
        </group>
        <group group_id="E9">
          <title>Placebo</title>
          <description>Cohorts 1, 2, 3, 4 and 5</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <description>Eosinophilia (55% ; 9.81 g/l). Concomitant medication taken; hospitalization/prolonged hospitalization. Outcome: Recovery</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4.17</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <description>Eosinophilia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <description>Abdominal Discomfort</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Diarrhea</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Eosinophilic</sub_title>
                <description>Gastroenteritis Eosinophilic</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Vomiting</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <description>Malaise</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>Nasopharyngitis Pathogen Unspecified</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT Increased</sub_title>
                <description>ALT Increased</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>AST Increased</sub_title>
                <description>AST Increased</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood Creatine Phosphokinase increased</sub_title>
                <description>Blood Creatine Phosphokinase increased</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="5" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <description>Hypercalcaemia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <description>Hyperkalaemia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <description>Back Pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Fiona Macintyre</name_or_title>
      <organization>Medicines for Malaria Venture</organization>
      <phone>0041 22 555 0319</phone>
      <email>macintyref@mmv.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

